This program aims to develop anti-CD11b therapeutic monoclonal antibody for immuno-oncology.

CD11b can mediate macrophage adhesion, migration, chemotaxis, and accumulation during the inflammatory processes. Scientists found CD11b contributes bone marrow cells development into a subtype of M1 macrophages, which a factor to prevent tumor growth. However, data have also shown that cancer cells interference with the CD11b activity and can convert bone marrow cells into M2 macrophages. Instead of suppressing tumor growth, M2 macrophages worthen the process. Because integrin CD11b and its role in macrophage polarization, it is believed, yet not proved, this integrin regulates the immune response during tumor progression.

Learn more: Next-IO™ Anti-CD11b Therapeutic Monoclonal Antibody Program